SE9704870D0 - New pharmaceutical formulation I - Google Patents

New pharmaceutical formulation I

Info

Publication number
SE9704870D0
SE9704870D0 SE9704870A SE9704870A SE9704870D0 SE 9704870 D0 SE9704870 D0 SE 9704870D0 SE 9704870 A SE9704870 A SE 9704870A SE 9704870 A SE9704870 A SE 9704870A SE 9704870 D0 SE9704870 D0 SE 9704870D0
Authority
SE
Sweden
Prior art keywords
dosage form
atpase inhibitor
pharmaceutical formulation
new pharmaceutical
released
Prior art date
Application number
SE9704870A
Other languages
English (en)
Swedish (sv)
Inventor
Per Johan Lundberg
Brita Sjoeblom
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9704870A priority Critical patent/SE9704870D0/xx
Publication of SE9704870D0 publication Critical patent/SE9704870D0/xx
Priority to ZA9811234A priority patent/ZA9811234B/xx
Priority to ARP980106245A priority patent/AR017202A1/es
Priority to TW087120441A priority patent/TWI240637B/zh
Priority to MA25384A priority patent/MA26577A1/fr
Priority to TNTNSN98230A priority patent/TNSN98230A1/fr
Priority to DZ980296A priority patent/DZ2686A1/xx
Priority to JP2000525085A priority patent/JP4907765B2/ja
Priority to NZ505135A priority patent/NZ505135A/en
Priority to IL13682398A priority patent/IL136823A/xx
Priority to DK98964632T priority patent/DK1043977T3/da
Priority to PT98964632T priority patent/PT1043977E/pt
Priority to PCT/SE1998/002369 priority patent/WO1999032093A1/en
Priority to US09/555,720 priority patent/US6610323B1/en
Priority to SK808-2000A priority patent/SK284545B6/sk
Priority to BR9814389-1A priority patent/BR9814389A/pt
Priority to AU19913/99A priority patent/AU759311B2/en
Priority to IDW20001201A priority patent/ID27040A/id
Priority to UA2000063359A priority patent/UA69396C2/ru
Priority to HU0200618A priority patent/HUP0200618A3/hu
Priority to PL98341565A priority patent/PL341565A1/xx
Priority to EP98964632A priority patent/EP1043977B1/en
Priority to ES98964632T priority patent/ES2209240T3/es
Priority to YU36600A priority patent/YU36600A/sh
Priority to CNB988137402A priority patent/CN1245155C/zh
Priority to SI9830589T priority patent/SI1043977T1/xx
Priority to AT98964632T priority patent/ATE252379T1/de
Priority to EEP200000395A priority patent/EE04417B1/xx
Priority to RU2000116012/14A priority patent/RU2205028C2/ru
Priority to KR1020007006907A priority patent/KR100616027B1/ko
Priority to TR2000/01982T priority patent/TR200001982T2/xx
Priority to CA002315927A priority patent/CA2315927C/en
Priority to CZ20002313A priority patent/CZ299227B6/cs
Priority to DE69819205T priority patent/DE69819205T2/de
Priority to EG158698A priority patent/EG23875A/xx
Priority to MYPI98005795A priority patent/MY130765A/en
Priority to HR20000381 priority patent/HRP20000381B1/xx
Priority to IS5541A priority patent/IS2184B/is
Priority to NO20003219A priority patent/NO20003219L/no
Priority to BG104619A priority patent/BG65008B1/bg
Priority to HK01105215A priority patent/HK1034668A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE9704870A 1997-12-22 1997-12-22 New pharmaceutical formulation I SE9704870D0 (sv)

Priority Applications (41)

Application Number Priority Date Filing Date Title
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I
ZA9811234A ZA9811234B (en) 1997-12-22 1998-12-08 Oral pharmaceutical pulsed release dosage form
ARP980106245A AR017202A1 (es) 1997-12-22 1998-12-09 Forma de dosificacion farmaceutica oral de liberacion pulsada y procedimiento para la preparacion de la misma y su uso para la manufactura de unmedicamento
TW087120441A TWI240637B (en) 1997-12-22 1998-12-09 Oral pharmaceutical pulsed release dosage form
MA25384A MA26577A1 (fr) 1997-12-22 1998-12-11 Formulation pharmaceutique orale a liberation pulsee
TNTNSN98230A TNSN98230A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale a liberation pulsee
DZ980296A DZ2686A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale à libération pulsée.
DE69819205T DE69819205T2 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform beruhend auf stossweiser freisetzung
UA2000063359A UA69396C2 (ru) 1997-12-22 1998-12-17 Пероральная фармацевтическая лекарственная форма с порционным высвобождением
CNB988137402A CN1245155C (zh) 1997-12-22 1998-12-17 口服药用脉冲释放剂型
IL13682398A IL136823A (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
DK98964632T DK1043977T3 (da) 1997-12-22 1998-12-17 Oral farmaceutisk doseringsform baseret på pulserende frigørelse
PT98964632T PT1043977E (pt) 1997-12-22 1998-12-17 Forma de dosagem farmaceutica oral de libertacao por impulsos
PCT/SE1998/002369 WO1999032093A1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
US09/555,720 US6610323B1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
SK808-2000A SK284545B6 (sk) 1997-12-22 1998-12-17 Orálna farmaceutická dávková forma s pulzačným uvoľňovaním
BR9814389-1A BR9814389A (pt) 1997-12-22 1998-12-17 Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
AU19913/99A AU759311B2 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
IDW20001201A ID27040A (id) 1997-12-22 1998-12-17 Bentuk sediaan dengan pelepasan berpulsa dari bahan farmasi oral
JP2000525085A JP4907765B2 (ja) 1997-12-22 1998-12-17 経口医薬パルス放出剤形
HU0200618A HUP0200618A3 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form and process for its preparation
PL98341565A PL341565A1 (en) 1997-12-22 1998-12-17 Oral dosage form featured by pulse-type release of active substance
EP98964632A EP1043977B1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
ES98964632T ES2209240T3 (es) 1997-12-22 1998-12-17 Formas de dosificacion farmaceutica oral de liberacion por pulsos.
YU36600A YU36600A (sh) 1997-12-22 1998-12-17 Oralni farmaceutski oblik za doziranje sa pulsnim oslobađanjem
NZ505135A NZ505135A (en) 1997-12-22 1998-12-17 Composition comprising a proton pump inhibitor (H+,K+-ATPase inhibitor) which provides two or more discrete release pulses in the small and/or large intestines
SI9830589T SI1043977T1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
AT98964632T ATE252379T1 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform beruhend auf stossweiser freisetzung
EEP200000395A EE04417B1 (et) 1997-12-22 1998-12-17 Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
RU2000116012/14A RU2205028C2 (ru) 1997-12-22 1998-12-17 Пероральная фармацевтическая лекарственная форма с дискретным высвобождением
KR1020007006907A KR100616027B1 (ko) 1997-12-22 1998-12-17 경구용 제약학적 펄스 방출형 투여 제형
TR2000/01982T TR200001982T2 (tr) 1997-12-22 1998-12-17 Farmasötik vurulu salınımlı oral dozaj şekli.
CA002315927A CA2315927C (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
CZ20002313A CZ299227B6 (cs) 1997-12-22 1998-12-17 Enterálne potažená farmaceutická dávková forma, zpusob prípravy a použití této dávkové formy, jakoži vrstvená tableta nebo peleta pro dávkovou formu
MYPI98005795A MY130765A (en) 1997-12-22 1998-12-21 Oral pharmaceutical pulsed release dosage form
EG158698A EG23875A (en) 1997-12-22 1998-12-21 Oral pharmaceutical pulsed release dosage form
HR20000381 HRP20000381B1 (en) 1997-12-22 2000-06-08 Stable complexes of poorly soluble compounds
IS5541A IS2184B (is) 1997-12-22 2000-06-19 Lyfjaform með áfangalosun til inntöku um munn
NO20003219A NO20003219L (no) 1997-12-22 2000-06-21 Oral farmasøytisk doseringsform med pulsert frigivningsvirkning
BG104619A BG65008B1 (bg) 1997-12-22 2000-07-17 Орална лекарствена дозирана форма с импулсно освобождаване
HK01105215A HK1034668A1 (en) 1997-12-22 2001-07-26 Oral pharmaceutical pulsed release dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I

Publications (1)

Publication Number Publication Date
SE9704870D0 true SE9704870D0 (sv) 1997-12-22

Family

ID=20409572

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I

Country Status (40)

Country Link
US (1) US6610323B1 (ru)
EP (1) EP1043977B1 (ru)
JP (1) JP4907765B2 (ru)
KR (1) KR100616027B1 (ru)
CN (1) CN1245155C (ru)
AR (1) AR017202A1 (ru)
AT (1) ATE252379T1 (ru)
AU (1) AU759311B2 (ru)
BG (1) BG65008B1 (ru)
BR (1) BR9814389A (ru)
CA (1) CA2315927C (ru)
CZ (1) CZ299227B6 (ru)
DE (1) DE69819205T2 (ru)
DK (1) DK1043977T3 (ru)
DZ (1) DZ2686A1 (ru)
EE (1) EE04417B1 (ru)
EG (1) EG23875A (ru)
ES (1) ES2209240T3 (ru)
HK (1) HK1034668A1 (ru)
HR (1) HRP20000381B1 (ru)
HU (1) HUP0200618A3 (ru)
ID (1) ID27040A (ru)
IL (1) IL136823A (ru)
IS (1) IS2184B (ru)
MA (1) MA26577A1 (ru)
MY (1) MY130765A (ru)
NO (1) NO20003219L (ru)
NZ (1) NZ505135A (ru)
PL (1) PL341565A1 (ru)
PT (1) PT1043977E (ru)
RU (1) RU2205028C2 (ru)
SE (1) SE9704870D0 (ru)
SK (1) SK284545B6 (ru)
TN (1) TNSN98230A1 (ru)
TR (1) TR200001982T2 (ru)
TW (1) TWI240637B (ru)
UA (1) UA69396C2 (ru)
WO (1) WO1999032093A1 (ru)
YU (1) YU36600A (ru)
ZA (1) ZA9811234B (ru)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
WO2000009092A1 (en) 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2596792A1 (en) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
AU2003301762B2 (en) * 2002-10-25 2006-02-09 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003297736A1 (en) * 2002-12-23 2004-07-29 Celltech Americas, Inc. Acid labile drug compositions
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
JP2004231520A (ja) * 2003-01-28 2004-08-19 Nichiko Pharmaceutical Co Ltd 保存安定性及び溶出速度に優れた医薬組成物
US8980322B2 (en) * 2003-03-17 2015-03-17 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2537477C (en) * 2003-09-03 2013-05-14 Boehringer Ingelheim International Gmbh Capsules containing active substance pellets with different release profiles
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005072079A2 (en) 2003-09-26 2005-08-11 Alza Coporation Drug coating providing high drug loading and methods for providing the same
WO2005030181A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
KR20060115860A (ko) * 2003-09-26 2006-11-10 알자 코포레이션 활성 제제의 서방성 전달을 위한 ｏｒｏｓ 푸시-스틱
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
JPWO2005092336A1 (ja) * 2004-03-26 2008-02-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 溶出制御製剤とその製造方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) * 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
AU2011205024B2 (en) * 2004-06-16 2012-09-06 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
US7226454B2 (en) * 2004-12-07 2007-06-05 Arizant Healthcare Inc. Warming device with varied permeability
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
EP1754471A1 (de) * 2005-08-18 2007-02-21 ORAMON-Arzneimittel GmbH & Co. KG Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
BRPI0620788A2 (pt) * 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
CN101460154B (zh) 2006-04-04 2015-07-01 Kg艾克维泽生公司 包含抗血小板剂和抑酸剂的口服剂型
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US20100104656A1 (en) * 2007-03-20 2010-04-29 Paul Wan Sia Heng Meltable Binder for Melt Granulation and/or Pelletization
CA2694602A1 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
KR20170097787A (ko) * 2007-10-12 2017-08-28 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
AU2009230676A1 (en) * 2008-03-24 2009-10-01 Lupin Limited Delayed release compositions of duloxetine
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
CA2766524A1 (en) * 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US10029089B2 (en) 2010-10-15 2018-07-24 Research Foundation For The State University Of New York, The Compositions and methods for enhancing the biological response to chemical agents and physical stimuli
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017146052A1 (ja) * 2016-02-23 2017-08-31 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
CN105796531A (zh) * 2016-04-13 2016-07-27 中国药科大学 一种右旋兰索拉唑择时脉冲控释微丸制剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6915258B2 (ja) * 2016-10-21 2021-08-04 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
RU2104084C1 (ru) 1989-02-16 1998-02-10 Бритиш Технолоджи Груп Лимитед Капсула дозируемого выброса
GB8903564D0 (en) 1989-02-16 1989-04-05 Rashid Abdul Drug dispensing device
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
JPH04273816A (ja) * 1991-02-26 1992-09-30 Tanabe Seiyaku Co Ltd パルス放出型有核錠
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
HUT78132A (hu) * 1994-07-08 2000-06-28 Astra Aktiebolag Omeprazol magnéziumsóját tartalmazó új orális gyógyszerforma
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
MX9600857A (es) 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals

Also Published As

Publication number Publication date
DK1043977T3 (da) 2004-02-09
CN1245155C (zh) 2006-03-15
NO20003219L (no) 2000-08-22
HK1034668A1 (en) 2001-11-02
YU36600A (sh) 2003-01-31
NO20003219D0 (no) 2000-06-21
HUP0200618A2 (hu) 2002-07-29
RU2205028C2 (ru) 2003-05-27
US6610323B1 (en) 2003-08-26
PT1043977E (pt) 2004-03-31
IS5541A (is) 2000-06-19
JP2001526213A (ja) 2001-12-18
CN1284868A (zh) 2001-02-21
BG65008B1 (bg) 2006-12-29
EE04417B1 (et) 2005-02-15
AR017202A1 (es) 2001-08-22
MA26577A1 (fr) 2004-12-20
CZ20002313A3 (cs) 2000-11-15
ZA9811234B (en) 1999-06-22
NZ505135A (en) 2002-06-28
DE69819205D1 (de) 2003-11-27
BG104619A (en) 2001-04-30
SK8082000A3 (en) 2001-02-12
ATE252379T1 (de) 2003-11-15
DZ2686A1 (fr) 2003-03-29
AU1991399A (en) 1999-07-12
HUP0200618A3 (en) 2003-04-28
PL341565A1 (en) 2001-04-23
SK284545B6 (sk) 2005-06-02
WO1999032093A1 (en) 1999-07-01
MY130765A (en) 2007-07-31
CA2315927A1 (en) 1999-07-01
HRP20000381A2 (en) 2000-12-31
HRP20000381B1 (en) 2004-12-31
AU759311B2 (en) 2003-04-10
DE69819205T2 (de) 2004-08-26
IS2184B (is) 2006-12-15
UA69396C2 (ru) 2004-09-15
CA2315927C (en) 2008-03-18
EP1043977A1 (en) 2000-10-18
BR9814389A (pt) 2000-10-10
TNSN98230A1 (fr) 2005-03-15
IL136823A0 (en) 2001-06-14
EE200000395A (et) 2002-02-15
TR200001982T2 (tr) 2001-02-21
TWI240637B (en) 2005-10-01
JP4907765B2 (ja) 2012-04-04
ID27040A (id) 2001-02-22
KR100616027B1 (ko) 2006-08-28
EG23875A (en) 2007-11-27
ES2209240T3 (es) 2004-06-16
KR20010033427A (ko) 2001-04-25
CZ299227B6 (cs) 2008-05-21
EP1043977B1 (en) 2003-10-22
IL136823A (en) 2005-08-31

Similar Documents

Publication Publication Date Title
SE9704870D0 (sv) New pharmaceutical formulation I
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
NO934284D0 (no) Farmas!ytisk preparat inneholdende et definert lipidsystem
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
HRP20020158B1 (en) Action of synergistic combination
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
DK1167354T3 (da) Racemisk huperzin A
PT880520E (pt) Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase
CA2225628A1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
SI0841904T1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
ES2082524T3 (es) Medicamento de liberacion retardada que contiene un derivado de dihidropiridina en forma de nanosol y su preparacion.
IT1270958B (it) Composizioni farmaceutiche a base di nimesulide, somministrabili per via orale, non gastrolesive e/o a rilascio controllato
NO920719L (no) Injiserbare s-adenosyl-l-metionin-holdige preparater